GLG Partners’s Antares Pharma, Inc. ATRS Stock Holding History

GLG Partners’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-85,363	Closed	-$242K	–	466
2017 Q1	$242K	Buy	+85,363	New	+$205K	0.01%	371

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GLG Partners's ATRS Position: Q2 2017 in Review

GLG Partners sold out of Antares Pharma, Inc. (ATRS) in Q2 2017, closing a stake of 85,363 shares — an estimated $242K sold.

GLG Partners first reported a position in ATRS in Q1 2017 and held it in 1 quarter. The position peaked at $242K in Q1 2017. 103 funds tracked by Wall St. Rank hold ATRS as of Q2 2017.

GLG Partners reported no remaining Antares Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
GLG Partners sold 85,363 Antares Pharma, Inc. shares in Q2 2017, an estimated $242K.
GLG Partners first reported a position in Antares Pharma, Inc. in Q1 2017 and held it in 1 quarter.
GLG Partners's Antares Pharma, Inc. position peaked at $242K in Q1 2017.
103 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2017.

Based on GLG Partners's 13F filing for Q2 2017, filed 14 Aug 2017.